1. In Vivo
  2. >>Deal-Making

In Vivo's Deals Of The Month, August 2016

 
• By Nancy Dvorin

In Vivo's editors pick August's most significant deals, including a neuromodulation joint venture and big money for a newish IO drug developer. (Article free with registration.)

GlaxoSmithKline PLC and Verily Life Sciences will invest up to £540 million ($702 million) over the next seven years in Galvani Bioelectronics, a new joint venture dedicated to breaching the next frontier in neuromodulation technologies. (Also see "New GSK-Verily JV Aims For Smart, 'Grain Of Rice' Neuromod Tech" - Medtech Insight, 2 August, 2016.) [See Deal] GSK, which will hold a 55% stake in the company, will contribute its drug development expertise, understanding of disease biology and know-how in getting clinical proof and evidence. Verily brings to the table its expertise in miniaturization technology, device development, as well as data analytics, machine learning and software development. Galvani's mission is to explore multiple areas within inflammatory, metabolic and endocrine disorders, including type 2 diabetes, where Verily already has existing product development collaborations with DexCom Inc. and Sanofi.

Ten-year old Tioma Therapeutics Inc., which is developing immunotherapies for solid and blood cancers, raised $86 million in a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Deals Shaping The Industry, June 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

More from In Vivo

Execs On The Move: June 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.